GUTS FRACTYL HEALTH INC

Fractyl Health to Participate in the Upcoming December Conferences

Fractyl Health to Participate in the Upcoming December Conferences

BURLINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will present at two upcoming investor conferences.

Details of the presentations can be found below.

7th Annual Evercore ISI HealthCONx Conference

Format: Fireside Chat

Date: 12/03/2024

Time: 7:30 AM ET

Piper Sandler 36th Annual Healthcare Conference

Format: Fireside Chat

Date: 12/04/2024

Time: 1:30 PM ET

Webcast replays will be accessible following the live sessions on the Events page of the Investors section on the Company’s website at .

About Fractyl Health

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit .

Contacts 

Corporate Contact 

Lisa Davidson, Chief Financial Officer 

, 781.902.8800

Media Contact 

Jessica Cotrone, Corporate Communications

, 978.760.5622

Investor Contact

Stephen Jasper Gilmartin Group

, 619.949.3681



EN
26/11/2024

Underlying

GUTSFRACTYL HEALTH INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FRACTYL HEALTH INC

 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing R...

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy 12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure Median weight remained stable through 3 months (0.46% / ~ 1 pound weight change within the margin of error for daily weight measurement), compared to expected 5–6% weight regain (10–15 pounds) after stopping GLP-1 therapy Revita co...

June 23, 2025 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Presents New Data at the American Diabetes Association’...

Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity Rejuva-treated healthy animals exposed to a high fat diet were protected from weight gain and hyperglycemia Data reinforce advancement of RJVA-001 toward first-in-human studies; preliminary clinical data expected in 2026 BURLINGTON, Mass., Ju...

June 23, 2025 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Reinforces Intellectual Property Leadership in Metaboli...

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing Robust intellectual property portfolio, built over more than a decade, designed to protect core innovations for treating metabolic diseases New U.S. patents strengthen Fractyl’s leadership in metabolic innovation by expanding its patent coverage of duodenal resurfacing, including thermal and non-thermal electrical energy applications BURLINGTON, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a m...

June 18, 2025 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart ...

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions BURLINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will present a poster of new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association’s (ADA) 85th Scient...

June 13, 2025 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Poten...

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide Collaboration is designed to implement a highly scalable clinical pathway for Revita in post GLP-1 weight maintenance, pending FDA approval, potentially benefiting millions of eligible patients Rising interest from patients and payers for an off-ramp from GLP-1 drugs is fueling significant demand for endoscopic alternatives designed to restore health rather than manage disease BURLINGTON, Mass. and SAN FRANCISCO, June 04, 2025 (GL...

June 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch